Navigation Links
SCAI Statement on 'A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study'
Date:5/6/2009

LAS VEGAS, May 6 /PRNewswire/ -- Results of the Clopidogrel Medco Outcomes Study presented today during SCAI's Annual Scientific Sessions found the anti-clotting benefits of clopidogrel (Plavix) may be reduced when taken concurrently with commonly used heartburn medications called proton pump inhibitors (PPIs). In the study, patients taking clopidogrel and a PPI experienced a:

  • 50% increase in the combined risk of hospitalization for heart attack, stroke, unstable angina, or repeat revascularization, including:
    • 70% increase in the risk of heart attack or unstable angina
    • 48% increase in the risk of stroke or stroke-like symptoms
    • 35% increase in the need for a repeat coronary procedure

Dual antiplatelet therapy, which commonly consists of clopidogrel and aspirin, is routinely prescribed to patients following insertion of stents to prevent life-threatening blood clots. PPIs are also frequently prescribed to these patients for brief periods (approximately 30 days) following stent insertion to treat unpleasant but non-life-threatening side effects of clopidogrel such as nausea. In some patients PPIs may also be taken routinely for gastrointestinal conditions like peptic ulcer disease.

The Clopidogrel Medco Outcomes Study is the largest to date to examine the outcomes of patients who are taking clopidogrel and a PPI. However, two smaller, earlier studies came to opposite conclusions concerning adverse effects when patients were taking both medications. The first study, a database analysis, found an increase in cardiac events in patients taking clopidogrel along with a PPI, while the CREDO study found no adverse effect when clopidogrel was taken along with a PPI.

The current study examined outcomes of patients taking common PPI medications including pantoprazole (Protonix), esomeprazole (Nexium), omeprazole (Prilosec), and lansoprazole (Prevacid). It did not review outcomes in patients taking any of the newer PPIs, such as rabeprazole (Aciphex) or dexlansoprazole (Kapidex). Patients in the study took PPIs for an average of nine months.

SCAI believes more research is needed on this topic. However, given the thousands of patients who receive stents each year, coupled with the significant risks demonstrated in this study, SCAI recommends the use of alternative medications for GI symptoms in patients with stents when appropriate. Other effective treatments for heartburn and ulcers include histaminergic (H2) blockers (Zantac, Tagamet) or antacids. In some patients the use of PPIs may still be warranted based on the patient's medical problems and should be taken at the direction of the patient's cardiologist, gastroenterologist or primary physician.

Importantly, patients should never stop taking any prescribed medication without first discussing with their doctor. Guidelines authored by SCAI and other cardiovascular organizations recommend dual-antiplatelet therapy for no less than one year following stent implantation. Clinical trials have shown this drug regimen effectively prevents blood clots that can lead to rare but potentially life-threatening cardiac events.


'/>"/>
SOURCE SCAI
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
(Date:2/10/2016)... 10, 2016 Convergence scenarios are ... various technologies that results in diverse solutions ... opportunities create a cyclical system where technology ... the development of new technologies. ... technology convergences, which are constantly fostering new ...
Breaking Medicine Technology: